Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17253755 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | December 2020 | February 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17251005 | Process for Preparation of Thiocyclam Base and Salt | December 2020 | August 2024 | Abandon | 44 | 1 | 0 | No | No |
| 16973119 | Compositions and Methods for the Diagnosis, Treatment and Prevention of Neoplastic and Neurological Disorders | December 2020 | May 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17059125 | METHOD OF PREPARING HIGH CHIRAL PURITY LACTAM INTERMEDIATE AND BRIVARACETAM | November 2020 | February 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17099455 | Compositions and Methods for Treating Sickle Cell Disease | November 2020 | May 2024 | Abandon | 42 | 2 | 0 | No | No |
| 17097768 | METHODS AND DRUG COMPOSITIONS FOR TREATING LYME DISEASE | November 2020 | June 2022 | Allow | 19 | 1 | 0 | Yes | No |
| 17096528 | USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR TREATMENT OF VASCULAR MALFORMATIONS | November 2020 | June 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17086101 | TREATMENT OF ADVANCED ESTROGEN RECEPTOR POSITIVE BREAST CANCER | October 2020 | May 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17082161 | METHOD OF REDUCING NEURONAL CELL DEATH WITH HALOALKYLAMINES | October 2020 | August 2022 | Abandon | 21 | 1 | 0 | No | No |
| 17074877 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | October 2020 | February 2022 | Allow | 16 | 1 | 0 | No | No |
| 17064000 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRAIN INJURY | October 2020 | October 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 17061018 | COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF | October 2020 | July 2022 | Abandon | 22 | 0 | 1 | No | No |
| 17039064 | PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS | September 2020 | August 2024 | Abandon | 46 | 3 | 0 | No | Yes |
| 17037070 | COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF | September 2020 | July 2022 | Abandon | 21 | 0 | 1 | No | No |
| 17023681 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | September 2020 | October 2022 | Allow | 25 | 2 | 0 | Yes | No |
| 17023738 | NOVEL ANTI-INFLAMMATORY COMPOUND, PRODUCING METHOD AND USE THEREOF | September 2020 | December 2023 | Abandon | 39 | 2 | 0 | No | No |
| 17018158 | COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS | September 2020 | July 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 16974023 | Compositions and methods including reverse thermal gels and pH adjustors | September 2020 | March 2023 | Abandon | 31 | 0 | 1 | No | No |
| 17002492 | PREPARATION OF (-)-COCAINE HYDROCHLORIDE | August 2020 | March 2023 | Abandon | 31 | 1 | 1 | No | No |
| 16969713 | PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES OR BONE DISEASES | August 2020 | December 2022 | Allow | 28 | 2 | 1 | Yes | No |
| 16989303 | TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFIT | August 2020 | August 2024 | Abandon | 48 | 2 | 1 | No | Yes |
| 16987515 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE | August 2020 | December 2021 | Abandon | 16 | 2 | 0 | No | No |
| 16942957 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | July 2020 | July 2024 | Abandon | 48 | 3 | 1 | Yes | Yes |
| 16966307 | REPURPOSING COMPOUNDS FOR THE TREATMENT OF INFECTIONS AND FOR MODULATING THE COMPOSITION OF THE GUT MICROBIOME | July 2020 | April 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 16965310 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF ALZHEIMER'S DISEASE IN PATIENTS HAVING LOST RESPONSIVENESS TO ACETYLCHOLINESTERASE INHIBITOR THERAPY | July 2020 | January 2024 | Abandon | 41 | 2 | 1 | No | No |
| 16930208 | METHOD OF PROVIDING CELIPROLOL THERAPY TO A PATIENT | July 2020 | October 2022 | Allow | 27 | 1 | 0 | Yes | No |
| 16961564 | COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS | July 2020 | October 2023 | Abandon | 39 | 2 | 1 | No | No |
| 16922500 | Composition for local tumescent anesthesia | July 2020 | June 2024 | Abandon | 47 | 3 | 1 | No | No |
| 16910860 | INHALABLE FORMULATION OF A SOLUTION CONTAINING FORMOTEROL FUMARATE AND ACLIDINIUM BROMIDE | June 2020 | November 2023 | Abandon | 40 | 2 | 1 | No | No |
| 16955220 | TREATMENT OF FIBROSIS WITH INOSITOL | June 2020 | October 2022 | Abandon | 28 | 1 | 0 | No | No |
| 16905300 | TOPICAL FORMULATION COMPRISING PENETRATION ENHANCERS | June 2020 | June 2022 | Abandon | 23 | 2 | 1 | No | No |
| 16772667 | USE OF METFORMIN SALT IN THE TREATMENT OF CEREBRAL INFARCTION | June 2020 | September 2022 | Allow | 27 | 2 | 0 | Yes | No |
| 16886693 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES FOR TREATING CHRONIC WOUNDS | May 2020 | February 2023 | Abandon | 33 | 2 | 0 | No | No |
| 16766419 | BISPHENOL COMPOUNDS | May 2020 | December 2023 | Abandon | 42 | 2 | 1 | Yes | No |
| 16880796 | COMPOSITIONS AND METHODS OF TREATING A SUBJECT WITH TAURINE AND DERIVATIVES THEREOF | May 2020 | August 2024 | Abandon | 51 | 3 | 1 | No | No |
| 16879511 | USE OF CELIPROLOL FOR TREATING VASCULAR EHLERS-DANLOS SYNDROME IN WOMEN DURING PREGNANCY AND PERIPARTUM PERIOD | May 2020 | September 2022 | Abandon | 28 | 2 | 0 | No | No |
| 16878507 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING ISOTHIOCYANATE FUNCTIONAL SURFACTANTS AND ASSOCIATED METHODS FOR TREATING BIOFILMS | May 2020 | February 2022 | Allow | 21 | 1 | 0 | Yes | No |
| 16764410 | TREATMENT OF SIDE EFFECTS OF BOTULINUM THERAPIES | May 2020 | March 2023 | Abandon | 34 | 0 | 1 | No | No |
| 15931132 | TOPICAL COMPOSITIONS COMPRISING BIMATOPROST AND METHODS FOR STIMULATING HAIR GROWTH THEREWITH | May 2020 | March 2022 | Abandon | 22 | 1 | 0 | No | No |
| 16872794 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | May 2020 | June 2023 | Abandon | 37 | 2 | 1 | Yes | No |
| 16872615 | ISOTHIOCYANATE FUNCTIONAL SURFACTANT AND ASSOCIATED METHOD OF USE | May 2020 | January 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 16871686 | COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS | May 2020 | November 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16867538 | USE OF ISOTHIOCYANATE FUNCTIONAL SURFACTANTS AS NRF2 INDUCERS TO TREAT EPIDERMOLYSIS BULLOSA SIMPLEX AND RELATED DISEASES | May 2020 | April 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 16865903 | USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE TO TREAT ADDICTIVE AND ALCOHOL-RELATED DISORDERS | May 2020 | March 2022 | Abandon | 22 | 1 | 0 | No | No |
| 16760146 | USE OF 2-HYDROXYOLEIC ACID FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND OTHER IMMUNE PATHOLOGIES | April 2020 | May 2023 | Allow | 37 | 4 | 1 | Yes | Yes |
| 16851242 | LIQUID PHARMACEUTICAL COMPOSITIONS | April 2020 | February 2023 | Allow | 34 | 4 | 1 | Yes | No |
| 16755698 | FORMULATION CONTAINING A-DECARBONIZED-5a ANDROSTANE COMPOUND FOR INCREASING WHITE BLOOD CELL AND USE THEREOF | April 2020 | April 2024 | Abandon | 48 | 4 | 1 | Yes | No |
| 16829657 | METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION | March 2020 | September 2024 | Abandon | 53 | 3 | 0 | No | Yes |
| 16829423 | USE OF GABOXADOL IN THE TREATMENT OF NARCOLEPSY | March 2020 | December 2023 | Abandon | 44 | 3 | 0 | Yes | Yes |
| 16650721 | USE OF METFORMIN AND ANALOGS THEREOF TO REDUCE RAN PROTEIN LEVELS IN THE TREATMENT OF NEUROLOGICAL DISORDERS | March 2020 | October 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16819061 | METHODS OF PROTECTING THE EYE HEALTH OF CHILDREN EXPOSED TO BLUE AND WHITE LIGHT | March 2020 | February 2023 | Abandon | 35 | 2 | 0 | No | No |
| 16812661 | LIPOIC ACID CHOLINE ESTER COMPOSITIONS AND METHODS TO GENERATE BIOCOMPATIBLE OPHTHALMIC FORMULATIONS | March 2020 | November 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16800111 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | February 2020 | March 2021 | Abandon | 13 | 1 | 1 | No | No |
| 16796250 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | February 2020 | June 2021 | Abandon | 16 | 1 | 0 | No | No |
| 16640107 | COMPOSITION COMPRISING A XANTOPHYLL AND AN OMEGA-3 FATTY ACID AND METHOD OF USE THEREOF | February 2020 | March 2024 | Abandon | 48 | 1 | 0 | No | No |
| 16639352 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CANCER, INFLAMMATION, OR IMMUNE RESPONSE | February 2020 | July 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16785073 | SOLUTE AND SOLUTE MIXTURE, AS WELL AS A COMPOSITION COMPRISING AT LEAST ONE SOLUTE, FOR USE IN THE PREVENTION OR TREATMENT OF COSMETIC OR PATHOLOGIC EFFLORESCENCES CAUSED BY AIRBORNE PARTICLES | February 2020 | April 2022 | Abandon | 26 | 2 | 1 | No | No |
| 16778274 | METHOD OF TREATING MEDULLOBLASTOMA WITH AN EZH2 INHIBITOR | January 2020 | September 2024 | Abandon | 55 | 4 | 0 | No | Yes |
| 16747189 | EFFICIENT STABILIZER IN CONTROLLING SELF ACCELERATED DECOMPOSITION TEMPERATURE OF PEROXYCARBOXYLIC ACID COMPOSITIONS WITH MINERAL ACIDS | January 2020 | February 2021 | Allow | 12 | 2 | 1 | Yes | No |
| 16631066 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE | January 2020 | April 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16736136 | ALTERNATIVE KETONE ESTERS AND PRODUCTION PROCESSES THEREOF | January 2020 | November 2021 | Abandon | 22 | 1 | 0 | No | No |
| 16734135 | FORMULATIONS OF (S)-3-(1-(9H-PURIN-6-YLAMINO)ETHYL)-8-CHLORO-2-PHENYLISOQUINOLIN-1(2H)-ONE | January 2020 | December 2021 | Allow | 24 | 2 | 1 | Yes | No |
| 16722754 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | December 2019 | October 2020 | Allow | 10 | 1 | 1 | Yes | No |
| 16722691 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | December 2019 | December 2020 | Allow | 12 | 1 | 1 | No | No |
| 16720511 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME | December 2019 | June 2022 | Abandon | 29 | 1 | 1 | No | No |
| 16620831 | SMALL-MOLECULE POVIDONE ANALOGS IN COAMORPHOUS PHARMACEUTICAL PHASES | December 2019 | December 2021 | Allow | 24 | 1 | 0 | Yes | No |
| 16618161 | USE OF METFORMIN AND SODIUM BUTYRATE FOR TREATING CONDITIONS INDUCED BY CHRONIC INFLAMMATION | November 2019 | May 2022 | Allow | 29 | 2 | 0 | Yes | No |
| 16697935 | ABUSE-DETERRENT DRUG FORMULATIONS | November 2019 | September 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16686057 | COMBINATION THERAPY FOR THE TREATMENT OF TINNITUS AND OTHER MEDICAL CONDITIONS | November 2019 | December 2023 | Abandon | 49 | 4 | 1 | Yes | No |
| 16675605 | METHODS AND DEVICES FOR USING ISOPERILLYL ALCOHOL | November 2019 | October 2021 | Abandon | 23 | 2 | 1 | No | No |
| 16664797 | TREATMENT OF CNS AND DEVELOPMENTAL DISORDERS USING HIGH-DOSE 5-FORMYL-(6S)-TETRAHYDROFOLATE | October 2019 | September 2024 | Abandon | 58 | 4 | 1 | Yes | Yes |
| 16662683 | METHYLNALTREXONE NASAL FORMULATIONS, METHODS OF MAKING, AND USE THEREOF | October 2019 | August 2021 | Allow | 22 | 1 | 0 | No | No |
| 16574701 | PHARMACEUTICAL COMPOSITION FOR ANO1 ANTAGONIST WITH ANTICANCER ACTIVITY | September 2019 | November 2021 | Allow | 25 | 2 | 1 | Yes | No |
| 16571881 | PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR ISCHEMIA TREATMENT | September 2019 | May 2022 | Abandon | 32 | 4 | 1 | Yes | No |
| 16570802 | TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME | September 2019 | January 2022 | Allow | 28 | 2 | 1 | Yes | No |
| 16568476 | METHOD OF TREATING OVARIAN CANCER USING ZETA-STAT | September 2019 | February 2024 | Abandon | 53 | 4 | 0 | No | No |
| 16493674 | TOBACCO- AND SMOKE-LESS PRODUCTS CONSUMABLE BY HUMANS AS EPICUREAN OR MEDICAL PRODUCTS AND METHOD OF TREATING SMOKING ADDICTION | September 2019 | April 2022 | Abandon | 31 | 2 | 1 | No | No |
| 16565917 | COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS | September 2019 | February 2022 | Allow | 29 | 1 | 1 | Yes | No |
| 16566811 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | September 2019 | April 2021 | Abandon | 19 | 0 | 1 | No | No |
| 16492284 | COMPOSITION FOR INHIBITING MYOFIBROSIS | September 2019 | October 2021 | Abandon | 25 | 1 | 1 | No | No |
| 16563726 | POST-SURGICAL PAIN TREATMENT | September 2019 | August 2023 | Abandon | 48 | 4 | 1 | No | No |
| 16491225 | SOLID STATE FORMS OF MIDOSTAURIN | September 2019 | March 2021 | Abandon | 18 | 0 | 1 | No | No |
| 16547734 | RIP2K INHIBITORS AND THEIR USE IN TREATING INFLAMMATORY DISEASES AND CONDITIONS | August 2019 | October 2021 | Abandon | 26 | 2 | 1 | No | No |
| 16526344 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | July 2019 | November 2020 | Allow | 15 | 1 | 0 | No | No |
| 16511726 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | July 2019 | June 2022 | Abandon | 35 | 2 | 0 | No | Yes |
| 16506119 | USE OF ISOTHIOCYANATE FUNCTIONAL SURFACTANTS AS NRF2 INDUCERS TO TREAT EPIDERMOLYSIS BULLOSA SIMPLEX AND RELATED DISEASES | July 2019 | February 2020 | Allow | 7 | 1 | 0 | Yes | No |
| 16504431 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH | July 2019 | November 2020 | Allow | 16 | 0 | 1 | Yes | No |
| 16444981 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | June 2019 | December 2020 | Allow | 18 | 2 | 0 | Yes | No |
| 16432539 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | June 2019 | July 2021 | Abandon | 26 | 2 | 1 | No | No |
| 16431255 | ISOTHIOCYANATE FUNCTIONAL SURFACTANT AND ASSOCIATED METHOD OF USE | June 2019 | March 2020 | Allow | 9 | 2 | 0 | Yes | No |
| 16415822 | COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH | May 2019 | July 2021 | Abandon | 26 | 1 | 1 | No | No |
| 16415075 | METHODS OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | May 2019 | November 2021 | Abandon | 30 | 2 | 0 | No | No |
| 16415779 | THERAPEUTIC AGENTS AND METHODS FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS | May 2019 | June 2022 | Abandon | 37 | 3 | 1 | No | No |
| 16412634 | MEANS FOR PROTECTING METHIONINE HYDROXY ANALOG FROM RUMEN DEGRADATION | May 2019 | September 2021 | Allow | 28 | 2 | 1 | Yes | No |
| 16413599 | USE OF RIFAMYCIN-QUINOLIZIDONE COUPLING MOLECULE | May 2019 | August 2021 | Abandon | 27 | 2 | 1 | No | No |
| 16413588 | USE OF RIFAMYCIN-NITROIMIDAZOLE COUPLING MOLECULE | May 2019 | August 2021 | Abandon | 27 | 2 | 1 | No | No |
| 16411398 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING ISOTHIOCYANATE FUNCTIONAL SURFACTANTS AND ASSOCIATED METHODS FOR TREATING BIOFILMS | May 2019 | March 2020 | Allow | 10 | 1 | 0 | Yes | No |
| 16410885 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | May 2019 | February 2021 | Allow | 21 | 1 | 1 | No | No |
| 16410747 | WATER SOLUBLE SALTS OF ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF DIABETIC COMPLICATIONS | May 2019 | October 2020 | Abandon | 17 | 0 | 1 | No | No |
| 16408424 | ATLERNATIVE KETONE ESTERS AND PRODUCTION PROCESSES THEREOF | May 2019 | January 2020 | Abandon | 9 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NEAGU, IRINA.
With a 18.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 19.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner NEAGU, IRINA works in Art Unit 1627 and has examined 593 patent applications in our dataset. With an allowance rate of 43.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.
Examiner NEAGU, IRINA's allowance rate of 43.5% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by NEAGU, IRINA receive 1.95 office actions before reaching final disposition. This places the examiner in the 44% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by NEAGU, IRINA is 27 months. This places the examiner in the 69% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +62.1% benefit to allowance rate for applications examined by NEAGU, IRINA. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.3% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 25.7% of cases where such amendments are filed. This entry rate is in the 37% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 83.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 66% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 62.1% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 80.6% are granted (fully or in part). This grant rate is in the 84% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.7% of allowed cases (in the 62% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.